Agios

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Agios and other ETFs, options, and stocks.

About AGIO

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. 

CEO
Brian M. Goff
CEOBrian M. Goff
Employees
540
Employees540
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2007
Founded2007
Employees
540
Employees540

AGIO Key Statistics

Market cap
1.61B
Market cap1.61B
Price-Earnings ratio
-3.86
Price-Earnings ratio-3.86
Dividend yield
Dividend yield
Average volume
924.88K
Average volume924.88K
High today
$27.59
High today$27.59
Low today
$26.84
Low today$26.84
Open price
$27.27
Open price$27.27
Volume
834.13K
Volume834.13K
52 Week high
$46.00
52 Week high$46.00
52 Week low
$22.24
52 Week low$22.24

Stock Snapshot

As of today, Agios(AGIO) shares are valued at $27.50. The company's market cap stands at 1.61B, with a P/E ratio of -3.86.

On 2026-03-06, Agios(AGIO) stock traded between a low of $26.84 and a high of $27.59. Shares are currently priced at $27.50, which is +2.5% above the low and -0.3% below the high.

The Agios(AGIO)'s current trading volume is 834.13K, compared to an average daily volume of 924.88K.

In the last year, Agios(AGIO) shares hit a 52-week high of $46.00 and a 52-week low of $22.24.

In the last year, Agios(AGIO) shares hit a 52-week high of $46.00 and a 52-week low of $22.24.

AGIO News

TipRanks 1d
Top Agios Pharma Executive Makes Notable Insider Move With Recent Stock Sale

New insider activity at Agios Pharma ( (AGIO) ) has taken place on March 5, 2026. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful inves...

TipRanks 2d
Citi ups Agios target, opens ‘upside 90-day catalyst watch’

Citi raised the firm’s price target on Agios Pharmaceuticals (AGIO) to $46 from $38 and keeps a Buy rating on the shares. Citi also placed an “upside 90-day cat...

Simply Wall St 3d
Agios Pharmaceuticals Is Down 6.3% After UAE Clears PYRUKYND As First Thalassemia Drug

Agios Pharmaceuticals recently announced that the Emirates Drug Establishment in the UAE approved PYRUKYND (mitapivat) as the first and only medicine for adult...

Agios Pharmaceuticals Is Down 6.3% After UAE Clears PYRUKYND As First Thalassemia Drug

Analyst ratings

70%

of 10 ratings
Buy
70%
Hold
30%
Sell
0%

More AGIO News

Simply Wall St 4d
A Look At Agios Pharmaceuticals Valuation After PYRUKYND UAE Thalassemia Approval

Advertisement Why PYRUKYND’s UAE approval is drawing fresh attention to Agios Pharmaceuticals The recent approval of PYRUKYND (mitapivat) in the United Arab E...

A Look At Agios Pharmaceuticals Valuation After PYRUKYND UAE Thalassemia Approval
TipRanks 5d
Agios Pharmaceuticals Pyrukynd approved for adults in UAE

Agios Pharmaceuticals (AGIO) announced that the Emirates Drug Establishment, EDE, of the United Arab Emirates, UAE, has approved Pyrukynd, an oral pyruvate kina...

People also own

Based on the portfolios of people who own AGIO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.